Evidence map›Paper›PMID 27301716›Full record

ArticleMolecular pharmacology2016

HSP90 Regulation of P2X7 Receptor Function Requires an Intact Cytoplasmic C-Terminus.

Keisuke Migita, Taku Ozaki, Shuji Shimoyama, Junko Yamada, Yoshikazu Nikaido, Tomonori Furukawa, Yuko Shiba, Terrance M Egan, Shinya Ueno

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. P2X7 Interactions and Signaling - Making Head or Tail of It.Frontiers in molecular neuroscience · 2019
    Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Keisuke MigitaDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.) migitak@fukuoka-u.ac.jp.
Taku OzakiDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Shuji ShimoyamaDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Junko YamadaDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Yoshikazu NikaidoDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Tomonori FurukawaDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Yuko ShibaDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Terrance M EganDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Shinya UenoDepartment of Drug Informatics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan (K.M.); Department of Neurophysiology (T.O., S.S., Y.N., T.F., Y.S., S.U.) and Research Center for Child Mental Development (T.O., S.S., S.U.), Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan; Department of Biomedical Sciences, Hirosaki University Graduate School of Health Sciences, Hirosaki, Aomori, Japan (J.Y.); and Department of Pharmacology and Physiology, and The Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri (T.M.E.).
Fukuoka University · JPHirosaki University · JPSaint Louis University · US

Funding

Gating and conduction of ATP-gated ion channelsR01GM070925 · NIGMS · SAINT LOUIS UNIVERSITY · PI EGAN, TERRANCE M · 2004 to 2007
$1.3M
NIGMS NIH HHS R01 GM070925
6 · The paper itself

Abstract

P2X7 receptors (P2X7Rs) are ATP-gated ion channels that display the unusual property of current facilitation during long applications of agonists. Here we show that facilitation disappears in chimeric P2X7Rs containing the C-terminus of the P2X2 receptor (P2X2R), and in a truncated P2X7R missing the cysteine-rich domain of the C-terminus. The chimeric and truncated receptors also show an apparent decreased permeability to N-methyl-d-glucamine(+) (NMDG(+)). The effects of genetic modification of the C-terminus on NMDG(+) permeability were mimicked by preapplication of the HSP90 antagonist geldanamycin to the wild-type receptor. Further, the geldanamycin decreased the shift in the reversal potential of the ATP-gated current measured under bi-ionic NMDG(+)/Na(+) condition without affecting the ability of the long application of agonist to facilitate current amplitude. Taken together, the results suggest that HSP90 may be essential for stabilization and function of P2X7Rs through an action on the cysteine-rich domain of the cytoplasmic the C-terminus.

Indexed as

Adenosine TriphosphateAnimalsBenzoquinonesCell MembraneCell Membrane PermeabilityCytoplasmHEK293 CellsHSP90 Heat-Shock ProteinsHumansIon Channel GatingLactams, MacrocyclicMeglumineMutant ProteinsProtein BindingProtein DomainsRatsAdenosine TriphosphateBenzoquinonesgeldanamycinHSP90 Heat-Shock ProteinsLactams, MacrocyclicMeglumineMutant ProteinsReceptors, Purinergic P2X7Recombinant Proteins

Identifiers

PMID27301716
PMCPMC11037447
OpenAlexW2429301312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.